{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00028997", "CSN": null, "TRF": "ORD_1618386_01", "MRN": "43273263", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1314511", "clinicalId": "1315858", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1618386_01", "SampleName": "US1544523.01", "Version": "0", "Sample": {"FM_Id": "ORD_1618386_01", "SampleId": "US1544523.01", "BlockId": "S112-16705A", "TRFNumber": "ORD_1618386_01", "TestType": "FoundationOne Heme", "SpecFormat": "FFPE", "ReceivedDate": "2023_04_27", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "7010 Kit Creek Road, Morrisville, NC 27560", "cliaNumber": "34D2044309", "locationID": "2", "locationName": "RTP", "processID": "2", "processName": "Extracted DNA"}]}, "TumorPurity": "35", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10095", "MRN": "43273263", "FullName": "\u9673\u4fd0\u4ea8", "FirstName": "Li Heng", "LastName": "Chen", "SubmittedDiagnosis": "Uterus endometrial stromal sarcoma, high grade", "Gender": "Female", "DOB": "1967_07_23", "OrderingMD": "\u738b\u9d6c\u60e0 ", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Soft Tissue", "CollDate": "2023_04_18", "ReceivedDate": "2023-05-12 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Uterine Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "24", "clinicalTrialCount": "16", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "BCOR", "isVUS": "true", "variantName": "A570T"}, {"geneName": "EMSY (C11orf30)", "isVUS": "true", "variantName": "K1143N"}, {"geneName": "ERG", "isVUS": "true", "variantName": "amplification"}, {"geneName": "KDM2B", "isVUS": "true", "variantName": "amplification,rearrangement,rearrangement"}, {"geneName": "KDM4C", "isVUS": "true", "variantName": "F907C"}, {"geneName": "MDM2", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "MSH2", "isVUS": "true", "variantName": "I169V"}, {"geneName": "NCOR2", "isVUS": "true", "variantName": "Q507_Q510del"}, {"geneName": "NUP93", "isVUS": "true", "variantName": "K633Q"}, {"geneName": "PTPN6", "isVUS": "true", "variantName": "K522T"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "S2292L"}, {"geneName": "TMPRSS2", "isVUS": "true", "variantName": "rearrangement,rearrangement"}, {"geneName": "TSC2", "isVUS": "true", "variantName": "S1269Y"}, {"geneName": "ZRSR2", "isVUS": "true", "variantName": "S439R"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CDK4", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "CDK4 encodes the cyclin_dependent kinase 4, which regulates the cell cycle, senescence, and apoptosis (reviewed in Choi et al., 2014; 23644662). CDK4 and its functional homolog CDK6 are activated by D_type cyclins and promote cell cycle progression by inactivating the tumor suppressor Rb (Weinberg et al., 1995; 7736585, Musgrove et al., 2011; 21734724). Amplification of the chromosomal region that includes CDK4 has been reported in multiple cancer types, including lung cancer, glioblastoma, and liposarcoma, and has been associated with overexpression of CDK4 protein (Wikman et al., 2005; 15543620, Rao et al., 2010; 19609742, Dickson et al., 2013; 23569312, Chung et al., 2009; 19574885, Ragazzini et al., 2004; 15024701, Dujardin et al., 2011; 21336260, Zhang et al., 2013; 23393200, Horvai et al., 2009; 19734852). One study identified amplification of the chromosomal region including CDK4 in 26% (5/19) of uterine adenosarcoma cases (Piscuoglio et al., 2015; 26592504). Another study reported copy number gain of CDK4, with associated overexpression of CDK4 protein in 6/16 Mullerian adenosarcoma cases (Lee et al., 2016; 27255164). Published data investigating the prognostic implications of CDK4 alterations in uterine sarcomas are limited (PubMed, Mar 2023). CDK4 amplification or activation may predict sensitivity to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib (Dickson et al., 2013; 23569312, Flaherty et al., 2012; 22090362, Patnaik et al., 2016; 27217383, Infante et al., 2016; 27542767). Clinical benefit has been reported for limited tumor types including patients with CDK4_amplified liposarcoma and sarcoma in response to treatment with abemaciclib (Dickson et al., 2019; ASCO Abstract 11004), palbociclib (Dickson et al., 2013; 23569312, Dickson et al., 2016; 27124835), and ribociclib (Peguero et al., 2016; ASCO Abstract 2528).", "Include": "true", "ClinicalTrialNote": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04282031", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04557449", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT02693535", "Include": "true"}, {"nctId": "NCT05262400", "Include": "true"}, {"nctId": "NCT03784014", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT04040205", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MDM2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins (Sdek et al., 2005; 16337594, Brady et al., 2005; 15632057, Li et al., 2004; 15053880). MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, overexpression or amplification of MDM2 may be oncogenic (Brown et al., 2009; 19935675, Cordon_Cardo et al., 1994; 8306343). Overexpression or amplification of MDM2 is frequent in cancer (Beroukhim et al., 2010; 20164920). Although two retrospective clinical studies suggest that MDM2 amplification may predict a short time_to_treatment failure on anti_PD_1/PD_L1 immune checkpoint inhibitors, with 4/5 patients with MDM2 amplification (Kato et al., 2017; 28351930) and 2/3 patients with MDM2 or MDM4 amplification (Singavi et al., 2017; ESMO Abstract 1140PD) experiencing tumor hyperprogression, amplification of MDM2 or MDM4 was not associated with shorter progression_free survival (PFS) in a retrospective analysis of non_small cell lung cancer (NSCLC) outcomes with immune checkpoint inhibitors (hazard ratio of 1.4, p=0.44)(Rizvi et al., 2018; 29337640). The latter study reported PFS of >2 months for 5/8 patients with MDM2/MDM4 amplification (Rizvi et al., 2018; 29337640). One study of uterine adenosarcomas found MDM2 amplification in 28% (5/18) of samples analyzed (Howitt et al., 2014; 25231023). A genomic sub_analysis of uterine adenosarcomas reported focal amplification of 12q14.1\u201015, harboring the MDM2 and CDK4 loci, in 26% (5/19) of cases; amplification was only observed in the mesenchymal component of the adenosarcoma samples (Geyer et al., 2017; 28267263, Piscuoglio et al., 2016; 26592504). Published data investigating the prognostic implications of MDM2 amplification in uterine sarcoma are limited (PubMed, Mar 2023). No significant association of MDM2 expression with survival was observed in one immunohistochemical analysis for 49 patients with uterine leiomyosarcoma (Blom et al., 1998; 9454661); the impact of MDM2 expression or amplification in other uterine sarcoma subtypes has not been assessed (PubMed, Mar 2023). MDM2 antagonists disrupt the MDM2_p53 interaction, thereby stabilizing p53 (Cheok et al., 2011; 20975744). Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents (Ohnstad et al., 2013; 23165797, Gamble et al., 2012; 21725357). Preliminary Phase 1 studies of the MDM2_p53 antagonist alrizomadlin (APG_115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%\u201338% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors (Zhang et al., 2019; ASCO Abstract 3124, Rasco et al., 2019; ASCO Abstract 3126). A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non_small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively (Tolcher et al., 2021; ASCO Abstract 2506). Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti_leukemic response rates of 33% (25/75) and 37% (11/30), respectively (Martinelli et al., 2016; EHA21 Abstract S504, Daver et al., 2018; ASH Abstract 767); clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera (Mascarenhas et al., 2019; ASH Abstract 134). The dual MDM2/MDM4 inhibitor ALRN_6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T_cell lymphoma in a Phase 2 study (Shustov et al., 2018; ASH Abstract 1623); responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma (Sallman et al., 2018; ASH Abstract 4066, Meric_Bernstam et al., 2017; ASCO Abstract 2505).", "Include": "true", "ClinicalTrialNote": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT04785196", "Include": "true"}, {"nctId": "NCT03449381", "Include": "true"}, {"nctId": "NCT05012397", "Include": "true"}, {"nctId": "NCT03611868", "Include": "true"}, {"nctId": "NCT05180695", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "BCOR", "Include": "true", "Alterations": {"Alteration": {"Name": "BCOR_ZC3H7B fusion", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "BCOR_ZC3H7B fusion"}}, "Interpretation": "BCOR encodes a transcriptional corepressor that interacts with BCL6 but not with related POZ domain_containing proteins (Huynh et al., 2000; 10898795). BCOR activity is required for normal development; de novo germline mutations in BCOR have been linked to syndromic microphthalmia_2 and oculofaciocardiodental syndrome (Ng et al., 2004; 15004558). Multiple BCOR_involving fusions with various partners including CCNB3, ZC3H7B, EP300, CREBBP, RARA, and MAML3 have been described in cancer (Pierron et al., 2012; 22387997, Kao et al., 2016; 27428733, Specht et al., 2016; 26752546, Panagopoulos et al., 2013; 23580382, Antonescu et al., 2014; 24285434, Yamamoto et al., 2010; 20807888, Machado et al., 2016; 27180056, Puls et al., 2014; 24805859, Peters et al., 2015; 25360585, Shibayama et al., 2015; 26037154, Li et al., 2016; 27228320, Pisapia et al., 2020; 32493417, Tauziede_Espariat et al., 2020; 33138864, Lin et al., 2020; 32156473, Lewis et al., 2018; 29192652, Lu et al., 2020; 32758369, Linos et al., 2020; 32352579, Torre et al., 2019; 30816933). The ZC3H7B_BCOR fusion observed here is similar to the t(X;22)(p11;q13) translocations reported in ossifying fibromyxoid tumors and high_grade endometrial stromal sarcoma, which usually have an aggressive disease course (Lin et al., 2020; 32156473, Lewis et al., 2018; 29192652, Lu et al., 2020; 32758369, Linos et al., 2020; 32352579, Mansor et al., 2019; 29901520, Ondic et al., 2020; 31938824, Chang et al., 2018; 29104083, Specht et al., 2016; 26752546, Panagopoulos et al., 2013; 23580382, Antonescu et al., 2014; 24285434). In sarcomas, the ZC3H7B_BCOR fusion has been identified in ossifying fibromyxoid tumors (OFMTs)(Linos et al., 2020; 32352579, Antonescu et al., 2014; 24285434), high_grade endometrial stromal sarcoma (Panagopoulos et al., 2013; 23580382, Lin et al., 2020; 32156473, Lewis et al., 2018; 29192652, Lu et al., 2020; 32758369, Mansor et al., 2019; 29901520, Ondic et al., 2020; 31938824, Chang et al., 2018; 29104083), and undifferentiated small blue round cell sarcomas (SBRCT)(Specht et al., 2016; 26752546). Published data investigating the prognostic implications of non_BCOR_CCNB3 alterations in solid tumors are generally limited (PubMed, Sep 2022). ZC3H7B_BCOR fusion_positive endometrial stromal sarcoma has been characterized as an independent group of high_grade endometrial stromal sarcoma that often shows unique morphological features such as microcyst containing myxoid material, cytoplasmic signet ring cell appearance, and haemangiopericytoma_like vascular pattern (Lu et al., 2020; 32758369, Ondic et al., 2020; 31938824, Mansor et al., 2019; 29901520). ZC3H7B_BCOR fusion_positive cases often exhibit aggressive disease courses and unfavorable outcomes (Lu et al., 2020; 32758369, Mansor et al., 2019; 29901520). There are no targeted therapies available to address BCOR alterations. BCOR fusions are characteristic of sarcomas such as small round cell tumors, high_grade endometrial stromal sarcomas, clear cell sarcomas of the kidney, and ossifying fibromyxoid tumors (NCCN Soft Tissue Sarcoma Guidelines, v2.2022, NCCN Uterine Neoplasms Guidelines, v1.2023) (Aldera et al., 2020; 32161069, Pierron et al., 2012; 22387997, Machado et al., 2016; 27180056, Puls et al., 2014; 24805859, Peters et al., 2015; 25360585, Shibayama et al., 2015; 26037154, Li et al., 2016; 27228320, Kallen et al., 2020; 32796172, Pfister et al., 2022; 34921008).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FRS2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "FRS2 encodes the fibroblast growth factor receptor (FGFR) substrate 2, an adaptor protein involved in FGFR signaling, which may also mediate signaling through EGFR, NTRK, and VEGF receptors (Kanodia et al., 2014; 24885272, Wu et al., 2003; 12974390, Chen et al., 2014; 24706887, Yan et al., 2002; 11877385). FRS2 amplification was found to correlate with overexpression in high_grade serous ovarian tumors, and FRS2 overexpression promoted tumorigenesis in a preclinical study (Luo et al., 2015; 25368431). FRS2 amplification is particularly prevalent in liposarcoma, where amplification of the 12q13_15 region of chromosome 12 is considered to be a hallmark genetic alteration, although the effects of amplification of CDK4 and MDM2, also located in this region, have been studied in more detail than FRS2 in this context (Pilotti et al., 1998; 9713346, Segura_S\u00e1nchez et al., 2006; 17214366). Amplification of FRS2 has been observed in 93%_100% of dedifferentiated liposarcoma, 32% of undifferentiated high_grade pleomorphic sarcoma, and 100% of well_differentiated liposarcoma (Wang et al., 2011; 21793095, Zhang et al., 2013; 23393200). Amplification of the 12p15 chromosomal region containing FRS2, but not CDK4 or MDM2, was found in 12.5% of high_grade serous ovarian carcinomas, and knockdown of FRS2 in these cells resulted in apoptosis, indicating that cells with 12p15 amplification require FRS2 (Luo et al., 2015; 25368431). There are no approved therapies that target alterations in FRS2. Amplification of FRS2 can lead to activation of the FGFR and MAPK_ERK pathways, and preliminary studies in liposarcoma cell lines have shown that cells with this alteration are sensitive to FGFR inhibitors (Zhang et al., 2013; 23393200, Luo et al., 2015; 25368431).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Several studies of endometrial stromal sarcoma (ESS) have reported an absence of MSI (Moinfar et al., 2004; 15581979, Amant et al., 2001; 11437928, Risinger et al., 1995; 7585651). In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, of which 25% were liposarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). However, reports of MSI in sarcomas in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, and small sample size in most studies (Monument et al., 2012; 23401795). In these smaller studies of soft tissue sarcoma, reports of MSI at any level have been rare, with the highest incidences between 11% (2/18) to 25% (10/40) of cases (Wooster al., 1994; 8162069, Kawaguchi et al., 2005; 15643505, Saito et al., 2003; 14562278, Suwa et al., 1999; 10370164, Garcia et al., 2006; 16619000, Aue et al., 1998; 9689926). Published data investigating the prognostic implications of MSI in uterine or endometrial sarcoma are limited (PubMed, Sep 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "STAT6", "Include": "true", "Alterations": {"Alteration": {"Name": "PCBP2_STAT6 fusion", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "PCBP2_STAT6 fusion"}}, "Interpretation": "STAT6 encodes a member of the STAT family of transcription factors; these proteins are phosphorylated in response to cytokine receptor signaling and act to transduce those signals to the cell nucleus where they activate transcription of a variety of genes. The STAT family of transcription factors are activated in response to signaling from the JAK kinases, and this signaling pathway is well known to be dysregulated in the context of hematological malignancies (Vainchenker and Constantinescu, 2013; 22869151, Bruns and Kaplan, 2005; 16213149). One or more STAT6 rearrangements observed here have not been characterized, and their effect on protein function is unknown; however, they have been reported in the context of cancer, which may indicate biological relevance. The frequency of STAT6 rearrangements in uterus/endometrial sarcoma has not been evaluated (PubMed, May 2023). Published data investigating the prognostic implications of STAT6 alterations in uterus/endometrial sarcoma are limited (PubMed, May 2023). There are no therapies available to directly target somatic alterations in STAT6, although phosphorylation and activation of STAT6 is known to be decreased by inhibitors of JAK2, such as ruxolitinib (Ritz et al., 2013; 23852366).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "02", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "02"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Endometrial stromal sarcoma (ESS) harbors a median TMB of 1.7 mutations per megabase (muts/Mb), and 1.2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Published data investigating the prognostic implications of tissue TMB in sarcoma are conflicting (PubMed, Feb 2023). High tissue TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380), but with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CDK4", "Alteration": "amplification", "Title": "A Study of BPI_1178 in Patients With Advanced Solid Tumor and HR+/HER2_ Breast Cancer", "StudyPhase": "PHASE 1/2", "Target": "CDK6, CDK4, ER, Aromatase", "Locations": "Shanghai (China)", "NCTID": "NCT04282031", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Study to Test the Safety and Tolerability of PF_07220060 in Participants With Advance Solid Tumors", "StudyPhase": "PHASE 1", "Target": "CDK4, Aromatase, ER", "Locations": "Wuhan (China), Zhengzhou (China), Xi an (China), Beijing (China), Nove Zamky (Slovakia), Bratislava (Slovakia), Praha 2 (Czechia), Edinburgh (United Kingdom), Manchester (United Kingdom), London (United Kingdom)", "NCTID": "NCT04557449", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD_1, CTLA_4, PD_L1, TRKB, ALK, TRKC, ROS1, TRKA, FGFRs", "Locations": "Hawaii, Washington, Oregon, California", "NCTID": "NCT02693535", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "A Study to Learn About the Study Medicine (Called PF_07220060 in Combination With PF_07104091) In Participants With Breast Cancer and Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "CDK2, Aromatase, CDK4, ER", "Locations": "Prague (Czechia), Washington, California, Michigan, Massachusetts, Texas, Merida (Mexico)", "NCTID": "NCT05262400", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "MOLECULAR PROFILING OF ADVANCED SOFT_TISSUE SARCOMAS", "StudyPhase": "PHASE 3", "Target": "ABL, KIT, ROS1, ALK, MET, ERBB2, EGFR, BRAF, MEK, PARP, PD_L1, CDK4, CDK6", "Locations": "Strasbourg (France), Dijon (France), Paris (France), Villejuif (France), Lyon (France), Clermont_Ferrand (France), Marseille (France), Saint_Herblain (France), Bordeaux (France)", "NCTID": "NCT03784014", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "California, Iowa, Wisconsin, Missouri, Florida", "NCTID": "NCT04040205", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS", "Locations": "Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Seongnam_si (Korea, Republic of), Xi an (China)", "NCTID": "NCT04589845", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "APG_115 in Combination With PD_1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_1, MDM2", "Locations": "Shanghai (China), Guangzhou (China)", "NCTID": "NCT04785196", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)", "StudyPhase": "PHASE 1", "Target": "MDM2", "Locations": "Tokyo, Chuo_ku (Japan), Stockholm (Sweden), Warsaw (Poland), Poznan (Poland), Berlin (Germany), G\u00f6ttingen (Germany), K\u00f6ln (Germany), T\u00fcbingen (Germany), Leuven (Belgium), Bruxelles (Belgium)", "NCTID": "NCT03449381", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "Milademetan in Advanced/Metastatic Solid Tumors", "StudyPhase": "PHASE 2", "Target": "MDM2", "Locations": "Washington, California, South Dakota, Missouri, New York, Ohio, Massachusetts, Tennessee, Texas", "NCTID": "NCT05012397", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "A Study of APG_115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MDM2, PD_1", "Locations": "Brisbane (Australia), South Brisbane (Australia), Bedford Park (Australia), Heidelberg (Australia), California, Arizona, Missouri, Arkansas, Ohio, Pennsylvania", "NCTID": "NCT03611868", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "HDM201 and Pazopanib in Patients With P53 Wild_type Advanced/Metastatic Soft Tissue Sarcomas", "StudyPhase": "PHASE 1/2", "Target": "FGFR3, KIT, FGFR1, VEGFRs, FGFR2, MDM2", "Locations": "Lyon (France)", "NCTID": "NCT05180695", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "22869151", "FullCitation": "Vainchenker W, et al. Oncogene (2013) pmid: 22869151", "Include": "true"}, {"number": "1", "ReferenceId": "16213149", "FullCitation": "Bruns HA, et al. Crit. Rev. Oncol. Hematol. (2006) pmid: 16213149", "Include": "true"}, {"number": "2", "ReferenceId": "23852366", "FullCitation": "Ritz O, et al. Oncotarget (2013) pmid: 23852366", "Include": "true"}, {"number": "3", "ReferenceId": "16337594", "FullCitation": "Sdek P, et al. Mol. Cell (2005) pmid: 16337594", "Include": "true"}, {"number": "4", "ReferenceId": "15632057", "FullCitation": "Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057", "Include": "true"}, {"number": "5", "ReferenceId": "15053880", "FullCitation": "Li M, et al. Mol. Cell (2004) pmid: 15053880", "Include": "true"}, {"number": "6", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "7", "ReferenceId": "8306343", "FullCitation": "Cordon_Cardo C, et al. Cancer Res. (1994) pmid: 8306343", "Include": "true"}, {"number": "8", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "9", "ReferenceId": "28351930", "FullCitation": "Kato S, et al. Clin. Cancer Res. (2017) pmid: 28351930", "Include": "true"}, {"number": "10", "ReferenceId": "29337640", "FullCitation": "Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640", "Include": "true"}, {"number": "11", "ReferenceId": "25231023", "FullCitation": "Howitt BE, et al. J. Pathol. (2015) pmid: 25231023", "Include": "true"}, {"number": "12", "ReferenceId": "28267263", "FullCitation": "Geyer FC, et al. Mol Oncol (2017) pmid: 28267263", "Include": "true"}, {"number": "13", "ReferenceId": "26592504", "FullCitation": "Piscuoglio S, et al. J. Pathol. (2016) pmid: 26592504", "Include": "true"}, {"number": "14", "ReferenceId": "9454661", "FullCitation": "Blom R, et al. Gynecol. Oncol. (1998) pmid: 9454661", "Include": "true"}, {"number": "15", "ReferenceId": "20975744", "FullCitation": "Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744", "Include": "true"}, {"number": "16", "ReferenceId": "23165797", "FullCitation": "Ohnstad HO, et al. Cancer (2013) pmid: 23165797", "Include": "true"}, {"number": "17", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "18", "ReferenceId": "23644662", "FullCitation": "Choi YJ, et al. Oncogene (2014) pmid: 23644662", "Include": "true"}, {"number": "19", "ReferenceId": "7736585", "FullCitation": "Cell (1995) pmid: 7736585", "Include": "true"}, {"number": "20", "ReferenceId": "21734724", "FullCitation": "Musgrove EA, et al. Nat. Rev. Cancer (2011) pmid: 21734724", "Include": "true"}, {"number": "21", "ReferenceId": "15543620", "FullCitation": "Wikman H, et al. Genes Chromosomes Cancer (2005) pmid: 15543620", "Include": "true"}, {"number": "22", "ReferenceId": "19609742", "FullCitation": "Rao SK, et al. J. Neurooncol. (2010) pmid: 19609742", "Include": "true"}, {"number": "23", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "24", "ReferenceId": "19574885", "FullCitation": "Chung L, et al. Am. J. Surg. Pathol. (2009) pmid: 19574885", "Include": "true"}, {"number": "25", "ReferenceId": "15024701", "FullCitation": "Ragazzini P, et al. Histol. Histopathol. (2004) pmid: 15024701", "Include": "true"}, {"number": "26", "ReferenceId": "21336260", "FullCitation": "Dujardin F, et al. Mod. Pathol. (2011) pmid: 21336260", "Include": "true"}, {"number": "27", "ReferenceId": "23393200", "FullCitation": "Zhang K, et al. Cancer Res. (2013) pmid: 23393200", "Include": "true"}, {"number": "28", "ReferenceId": "19734852", "FullCitation": "Horvai AE, et al. Mod. Pathol. (2009) pmid: 19734852", "Include": "true"}, {"number": "29", "ReferenceId": "27255164", "FullCitation": "Lee JC, et al. Mod. Pathol. (2016) pmid: 27255164", "Include": "true"}, {"number": "30", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "31", "ReferenceId": "27217383", "FullCitation": "Patnaik A, et al. Cancer Discov (2016) pmid: 27217383", "Include": "true"}, {"number": "32", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "33", "ReferenceId": "27124835", "FullCitation": "Dickson MA, et al. JAMA Oncol (2016) pmid: 27124835", "Include": "true"}, {"number": "34", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "35", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "36", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "37", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "38", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "39", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "40", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "41", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "42", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "43", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "44", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "45", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "46", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "47", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "48", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "49", "ReferenceId": "30889380", "FullCitation": "Steele CD, et al. Cancer Cell (2019) pmid: 30889380", "Include": "true"}, {"number": "50", "ReferenceId": "31699828", "FullCitation": "Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828", "Include": "true"}, {"number": "51", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "52", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "53", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "54", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "55", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "56", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "57", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "58", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "59", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "60", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "61", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "62", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "63", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "64", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "65", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "66", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "67", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "68", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "69", "ReferenceId": "15581979", "FullCitation": "Moinfar F, et al. Gynecol. Oncol. (2004) pmid: 15581979", "Include": "true"}, {"number": "70", "ReferenceId": "11437928", "FullCitation": "Amant F, et al. Int. J. Gynecol. Cancer () pmid: 11437928", "Include": "true"}, {"number": "71", "ReferenceId": "7585651", "FullCitation": "Risinger JI, et al. Cancer Res. (1995) pmid: 7585651", "Include": "true"}, {"number": "72", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "73", "ReferenceId": "23401795", "FullCitation": "Monument MJ, et al. ISRN Oncol (2012) pmid: 23401795", "Include": "true"}, {"number": "74", "ReferenceId": "8162069", "FullCitation": "Wooster R, et al. Nat. Genet. (1994) pmid: 8162069", "Include": "true"}, {"number": "75", "ReferenceId": "15643505", "FullCitation": "Kawaguchi K, et al. Oncol. Rep. (2005) pmid: 15643505", "Include": "true"}, {"number": "76", "ReferenceId": "14562278", "FullCitation": "Saito T, et al. Hum. Pathol. (2003) pmid: 14562278", "Include": "true"}, {"number": "77", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "78", "ReferenceId": "16619000", "FullCitation": "Garcia JJ, et al. Mod. Pathol. (2006) pmid: 16619000", "Include": "true"}, {"number": "79", "ReferenceId": "9689926", "FullCitation": "Aue G, et al. Cancer Genet. Cytogenet. (1998) pmid: 9689926", "Include": "true"}, {"number": "80", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "81", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "82", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "83", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "84", "ReferenceId": "10898795", "FullCitation": "Huynh KD, et al. Genes Dev. (2000) pmid: 10898795", "Include": "true"}, {"number": "85", "ReferenceId": "15004558", "FullCitation": "Ng D, et al. Nat. Genet. (2004) pmid: 15004558", "Include": "true"}, {"number": "86", "ReferenceId": "22387997", "FullCitation": "Pierron G, et al. Nat. Genet. (2012) pmid: 22387997", "Include": "true"}, {"number": "87", "ReferenceId": "27428733", "FullCitation": "Kao YC, et al. Am. J. Surg. Pathol. (2016) pmid: 27428733", "Include": "true"}, {"number": "88", "ReferenceId": "26752546", "FullCitation": "Specht K, et al. Am. J. Surg. Pathol. (2016) pmid: 26752546", "Include": "true"}, {"number": "89", "ReferenceId": "23580382", "FullCitation": "Panagopoulos I, et al. Genes Chromosomes Cancer (2013) pmid: 23580382", "Include": "true"}, {"number": "90", "ReferenceId": "24285434", "FullCitation": "Antonescu CR, et al. Genes Chromosomes Cancer (2014) pmid: 24285434", "Include": "true"}, {"number": "91", "ReferenceId": "20807888", "FullCitation": "Yamamoto Y, et al. Blood (2010) pmid: 20807888", "Include": "true"}, {"number": "92", "ReferenceId": "27180056", "FullCitation": "Machado I, et al. Ann Diagn Pathol (2016) pmid: 27180056", "Include": "true"}, {"number": "93", "ReferenceId": "24805859", "FullCitation": "Puls F, et al. Am. J. Surg. Pathol. (2014) pmid: 24805859", "Include": "true"}, {"number": "94", "ReferenceId": "25360585", "FullCitation": "Peters TL, et al. Mod. Pathol. (2015) pmid: 25360585", "Include": "true"}, {"number": "95", "ReferenceId": "26037154", "FullCitation": "Shibayama T, et al. Pathol. Int. (2015) pmid: 26037154", "Include": "true"}, {"number": "96", "ReferenceId": "27228320", "FullCitation": "Li WS, et al. Histopathology (2016) pmid: 27228320", "Include": "true"}, {"number": "97", "ReferenceId": "32493417", "FullCitation": "Pisapia DJ, et al. Acta Neuropathol Commun (2020) pmid: 32493417", "Include": "true"}, {"number": "98", "ReferenceId": "33138864", "FullCitation": "Tauzi\u00e8de_Espariat A, et al. Acta Neuropathol Commun (2020) pmid: 33138864", "Include": "true"}, {"number": "99", "ReferenceId": "32156473", "FullCitation": "Lin DI, et al. Gynecol Oncol (2020) pmid: 32156473", "Include": "true"}, {"number": "100", "ReferenceId": "29192652", "FullCitation": "Lewis N, et al. Mod Pathol (2018) pmid: 29192652", "Include": "true"}, {"number": "101", "ReferenceId": "32758369", "FullCitation": "Lu B, et al. Pathology (2020) pmid: 32758369", "Include": "true"}, {"number": "102", "ReferenceId": "32352579", "FullCitation": "Linos K, et al. J Cutan Pathol (2020) pmid: 32352579", "Include": "true"}, {"number": "103", "ReferenceId": "30816933", "FullCitation": "Torre M, et al. J. Neuropathol. Exp. Neurol. (2019) pmid: 30816933", "Include": "true"}, {"number": "104", "ReferenceId": "29901520", "FullCitation": "Mansor S, et al. Int J Gynecol Pathol (2019) pmid: 29901520", "Include": "true"}, {"number": "105", "ReferenceId": "31938824", "FullCitation": "Ondi\u010d O, et al. Virchows Arch (2020) pmid: 31938824", "Include": "true"}, {"number": "106", "ReferenceId": "29104083", "FullCitation": "Chang KTE, et al. J Mol Diagn (2018) pmid: 29104083", "Include": "true"}, {"number": "107", "ReferenceId": "32161069", "FullCitation": "Aldera AP, et al. J Clin Pathol (2020) pmid: 32161069", "Include": "true"}, {"number": "108", "ReferenceId": "32796172", "FullCitation": "Kallen ME, et al. Am J Surg Pathol (2021) pmid: 32796172", "Include": "true"}, {"number": "109", "ReferenceId": "34921008", "FullCitation": "Pfister SM, et al. Cancer Discov (2022) pmid: 34921008", "Include": "true"}, {"number": "110", "ReferenceId": "24885272", "FullCitation": "Kanodia J, et al. Cell Commun. Signal (2014) pmid: 24885272", "Include": "true"}, {"number": "111", "ReferenceId": "12974390", "FullCitation": "Wu Y, et al. Biol. Chem. (2003) pmid: 12974390", "Include": "true"}, {"number": "112", "ReferenceId": "24706887", "FullCitation": "Chen PY, et al. Proc. Natl. Acad. Sci. U.S.A. (2014) pmid: 24706887", "Include": "true"}, {"number": "113", "ReferenceId": "11877385", "FullCitation": "Yan KS, et al. J. Biol. Chem. (2002) pmid: 11877385", "Include": "true"}, {"number": "114", "ReferenceId": "25368431", "FullCitation": "Luo LY, et al. Mol. Cancer Res. (2015) pmid: 25368431", "Include": "true"}, {"number": "115", "ReferenceId": "9713346", "FullCitation": "Pilotti S, et al. J. Pathol. (1998) pmid: 9713346", "Include": "true"}, {"number": "116", "ReferenceId": "17214366", "FullCitation": "Segura_S\u00e1nchez J, et al. Anticancer Res. () pmid: 17214366", "Include": "true"}, {"number": "117", "ReferenceId": "21793095", "FullCitation": "Wang X, et al. Genes Chromosomes Cancer (2011) pmid: 21793095", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_05_09 19:46:42", "OpName": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "771x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "2 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "UTERUS", "disease_ontology": "Uterus endometrial stromal sarcoma", "flowcell_analysis": "2000028952", "gender": "female", "pathology_diagnosis": "Endometrial Stromal Sarcoma", "percent_tumor_nuclei": "35", "pipeline_version": "v3.22.0", "purity_assessment": "76.02", "specimen": "ORD_1618386_01*US1544523.01", "study": "CLINICAL_HEME_COMPLETE", "test_request": "ORD_1618386_01", "test_type": "HemeComplete", "tissue_of_origin": "Soft Tissue", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": [{"bait_set": "R2", "mean_exon_depth": "477.75", "name": "SQ_US1544523.01_1", "nucleic_acid_type": "RNA"}, {"bait_set": "D2", "mean_exon_depth": "816.37", "name": "SQ_US1544523.01_2", "nucleic_acid_type": "DNA"}]}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4781", "cds_effect": "3806C>A", "depth": "479", "equivocal": "false", "functional_effect": "missense", "gene": "TSC2", "percent_reads": "47.81", "position": "chr16:2131791", "protein_effect": "S1269Y", "status": "unknown", "strand": "+", "transcript": "NM_000548", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.5818", "cds_effect": "6875C>T", "depth": "691", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "58.18", "position": "chr1:16259610", "protein_effect": "S2292L", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.06", "cds_effect": "1520_1531delAGCAGCAGCAGC", "depth": "150", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "NCOR2", "percent_reads": "6.0", "position": "chr12:124887058", "protein_effect": "Q507_Q510del", "status": "unknown", "strand": "_", "subclonal": "true", "transcript": "NM_006312", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.5378", "cds_effect": "2720T>G", "depth": "437", "equivocal": "false", "functional_effect": "missense", "gene": "KDM4C", "percent_reads": "53.78", "position": "chr9:7128175", "protein_effect": "F907C", "status": "unknown", "strand": "+", "transcript": "NM_015061", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.3193", "cds_effect": "1317C>G", "depth": "927", "equivocal": "false", "functional_effect": "missense", "gene": "ZRSR2", "percent_reads": "31.93", "position": "chrX:15841233", "protein_effect": "S439R", "status": "unknown", "strand": "+", "transcript": "NM_005089", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.1802", "cds_effect": "1565A>C", "depth": "716", "equivocal": "false", "functional_effect": "missense", "gene": "PTPN6", "percent_reads": "18.02", "position": "chr12:7069386", "protein_effect": "K522T", "status": "unknown", "strand": "+", "transcript": "NM_080549", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.158", "cds_effect": "3429G>T", "depth": "633", "equivocal": "false", "functional_effect": "missense", "gene": "EMSY", "percent_reads": "15.8", "position": "chr11:76256996", "protein_effect": "K1143N", "status": "unknown", "strand": "+", "transcript": "NM_020193", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.4644", "cds_effect": "1897A>C", "depth": "661", "equivocal": "false", "functional_effect": "missense", "gene": "NUP93", "percent_reads": "46.44", "position": "chr16:56870627", "protein_effect": "K633Q", "status": "unknown", "strand": "+", "transcript": "NM_014669", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.4855", "cds_effect": "1708G>A", "depth": "964", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "48.55", "position": "chrX:39932891", "protein_effect": "A570T", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.4906", "cds_effect": "505A>G", "depth": "954", "equivocal": "false", "functional_effect": "missense", "gene": "MSH2", "percent_reads": "49.06", "position": "chr2:47637371", "protein_effect": "I169V", "status": "unknown", "strand": "+", "transcript": "NM_000251", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "23", "equivocal": "false", "gene": "FRS2", "number_of_exons": "5 of 5", "position": "chr12:69962778_69968735", "ratio": "5.27", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"copy_number": "61", "equivocal": "false", "gene": "MDM2", "number_of_exons": "11 of 11", "position": "chr12:69202199_69233685", "ratio": "13.91", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"copy_number": "32", "equivocal": "false", "gene": "KDM2B", "number_of_exons": "26 of 26", "position": "chr12:121867877_122018818", "ratio": "7.35", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"copy_number": "18", "equivocal": "false", "gene": "ERG", "number_of_exons": "10 of 10", "position": "chr21:39755324_39947669", "ratio": "4.04", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"copy_number": "58", "equivocal": "false", "gene": "CDK4", "number_of_exons": "7 of 7", "position": "chr12:58142289_58145500", "ratio": "13.28", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}]}, "rearrangements": {"rearrangement": [{"description": "fusion", "equivocal": "false", "in_frame": "Yes", "other_gene": "ZC3H7B", "pos1": "chrX:39930265_39930305", "pos2": "chr22:41735107_41735147", "status": "known", "supporting_read_pairs": "436", "targeted_gene": "BCOR", "type": "fusion", "rna_evidence": {"sample": "SQ_US1544523.01_1"}}, {"allele_fraction": "0.0192", "description": "KDM2B(NM_032590) rearrangement intron 8", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "percent_reads": "1.92", "pos1": "chr12:121959045", "pos2": "chr12:69184004", "status": "unknown", "supporting_read_pairs": "25", "targeted_gene": "KDM2B", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.0104", "description": "MGAT4C(NM_013244)_TMPRSS2(NM_005656) fusion (M3; T4)", "equivocal": "false", "in_frame": "unknown", "other_gene": "MGAT4C", "percent_reads": "1.04", "pos1": "chr21:42862240", "pos2": "chr12:86672847", "status": "unknown", "supporting_read_pairs": "171", "targeted_gene": "TMPRSS2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"description": "PCBP2(NM_005016)_STAT6(NM_003153) fusion (P5; S2)", "equivocal": "false", "in_frame": "unknown", "other_gene": "PCBP2", "pos1": "chr12:57502082", "pos2": "chr12:53849785", "status": "likely", "supporting_read_pairs": "338", "targeted_gene": "STAT6", "type": "fusion", "rna_evidence": {"sample": "SQ_US1544523.01_1"}}, {"allele_fraction": "0.0214", "description": "PPM1H(NM_020700)_KDM2B(NM_032590) fusion (P8; K2*)", "equivocal": "false", "in_frame": "unknown", "other_gene": "PPM1H", "percent_reads": "2.14", "pos1": "chr12:122016844", "pos2": "chr12:63070219", "status": "unknown", "supporting_read_pairs": "270", "targeted_gene": "KDM2B", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.0166", "description": "TMTC2(NM_152588)_MDM2(NM_002392) fusion (T2*; M3)", "equivocal": "false", "in_frame": "unknown", "other_gene": "TMTC2", "percent_reads": "1.66", "pos1": "chr12:69207232", "pos2": "chr12:83250882", "status": "unknown", "supporting_read_pairs": "244", "targeted_gene": "MDM2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}, {"allele_fraction": "0.0085", "description": "TMPRSS2(NM_005656) rearrangement intron 1", "equivocal": "false", "in_frame": "unknown", "other_gene": "TRHDE", "percent_reads": "0.85", "pos1": "chr21:42872100", "pos2": "chr12:72850336", "status": "unknown", "supporting_read_pairs": "68", "targeted_gene": "TMPRSS2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1544523.01_2"}}]}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.44", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}